VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS10006826 | HBV | ENSG00000128683.14 | protein_coding | GAD1 | No | No | 2571 | A0A0S2Z3V5 Q8IVA8 Q99259 |
TVIS44024716 | HTLV-1 | ENSG00000128683.14 | protein_coding | GAD1 | No | No | 2571 | A0A0S2Z3V5 Q8IVA8 Q99259 |
TVIS44029565 | HTLV-1 | ENSG00000128683.14 | protein_coding | GAD1 | No | No | 2571 | A0A0S2Z3V5 Q8IVA8 Q99259 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | GAD1 |
---|---|
DrugBank ID | DB00142 |
Drug Name | Glutamic acid |
Target ID | BE0000378 |
UniProt ID | Q99259 |
Regulation Type | |
PubMed IDs | 17562689; 16769115; 17600364; 16643338; 17445798 |
Citations | Akama K, Takaiwa F: C-terminal extension of rice glutamate decarboxylase (OsGAD2) functions as an autoinhibitory domain and overexpression of a truncated mutant results in the accumulation of extremely high levels of GABA in plant cells. J Exp Bot. 2007;58(10):2699-707. Epub 2007 Jun 11.@@Tueting P, Doueiri MS, Guidotti A, Davis JM, Costa E: Reelin down-regulation in mice and psychosis endophenotypes. Neurosci Biobehav Rev. 2006;30(8):1065-77.@@Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J: Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol. 2007 Jun;61(6):544-51.@@Wang FY, Zhu RM, Maemura K, Hirata I, Katsu K, Watanabe M: Expression of gamma-aminobutyric acid and glutamic acid decarboxylases in rat descending colon and their relation to epithelial differentiation. Chin J Dig Dis. 2006;7(2):103-8.@@Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M: Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007 Jul 2;566(1-3):94-102. Epub 2007 Mar 24. |
Groups | Approved; Nutraceutical |
Direct Classification | Glutamic acid and derivatives |
SMILES | N[C@@H](CCC(O)=O)C(O)=O |
Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
PharmGKB | PA449776 |
ChEMBL | CHEMBL575060 |